Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL27467554 | 1.00 | DNM1 (0.50) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL288211 | 1.00 | DNM1 (0.50) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL21981130 | 1.00 | DNM1 (0.50) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL28107057 | 0.97 | TP53 (0.48) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL28986375 | 0.97 | TP53 (0.48) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL28157516 | 0.97 | TP53 (0.48) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL27959281 | 0.97 | TP53 (0.48) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL28172152 | 0.97 | TP53 (0.48) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL27417214 | 0.95 | TP53 (0.46) | DNM1APPTP53MEN1KMT2A | |
| Butylamine SCHEMBL28262920 | 0.95 | TP53 (0.46) | DNM1APPTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115193219-A | For absorbing CO 2 Solution of gas and CO 2 Absorption and release method of | 中国科学院物理研究所 | 2022-10-18 | — | — | CN | claimed |
| CN-111229451-B | Flotation separation method of talc and chalcopyrite | 中南大学 | 2021-06-15 | — | — | CN | claimed |
| CN-111229451-A | Flotation separation method of talc and chalcopyrite | 中南大学 | 2020-06-05 | — | — | CN | claimed |
| WO-2020016903-A1 | AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF PYRROLE DERIVATIVES WITH IMPROVED IMPURITY PROFILE & MINIMISATION OF UNIT OPERATIONS. | ARCH PHARMALABS LIMITED (IN) | 2020-01-23 | — | — | WO | claimed |
| CN-108468204-A | The preparation method of antibacterial inorganic metal salt cellulose fibre | 深圳市彩铜时代科技有限公司 | 2018-08-31 | — | — | CN | claimed |
| US-9790603-B2 | Process and catalyst-electrolyte combination for electrolysis | AQUAHYDREX PTY LTD (AU) | 2017-10-17 | — | — | US | claimed |
| CN-105085420-A | Method for catalytically synthesizing phenazine compounds in water phase under microwave radiation | UNIV FUJIAN MEDICAL | 2015-11-25 | — | — | CN | claimed |
| CN-104803969-A | Acrylic acid type thiosulfonate-based monomer with high refractive index and synthesis method of acrylic acid type thiosulfonate-based monomer | UNIV HEFEI TECHNOLOGY | 2015-07-29 | — | — | CN | claimed |
| EP-0817777-A1 | PROCESS FOR PREPARING 1,1'- 1,4-PHENYLENEBIS-(METHYLENE)]-BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1998-01-14 | — | — | EP | claimed |
| WO-1996030349-A1 | PROCESS FOR PREPARING 1,1'-[1,4-PHENYLENEBIS-(METHYLENE)]-BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE | JOHNSON MATTHEY PLC (GB) | 1996-10-03 | — | — | WO | claimed |
| US-4281105-A | Formation of particulate polypyrrolidone | BARNES CARL E | 1981-07-28 | — | — | US | claimed |
| US-4247685-A | Continuous bulk polymerization of 2-pyrrolidone | BARNES CARL E | 1981-01-27 | — | — | US | claimed |
| US-12618000-B2 | Friction reduction of acidic treatment fluids | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260071533-A1 | TREATMENT FLUID SELECTION | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247165-B2 | Anti-syneresis agents for fracturing operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20250075122-A1 | ADDITIVES TO PREVENT THERMAL THINNING IN POLYMER GEL SYSTEMS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-4005131-A | METAL SALT CATALYST, AMINE BASE | ATLANTIC RICHFIELD COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-4005129-A | OXALATE ESTERS | ATLANTIC RICHFIELD COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-3992436-A | Synthesis of oxalate esters from carbon monoxide and carboxylic ortho esters | ATLANTIC RICHFIELD COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3992428-A | REACTING UREA AND HEXAMETHYLDISILAZANE IN THE PRESENCE OF A NITROGEN CONTAINING SALT | WACKER-CHEMIE GMBH (DT) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071533-A1 | TREATMENT FLUID SELECTION | PLG, SOST, CSTB | DNM1 310/4885APP 296/4885TP53 2704/4885 |
| US-12618000-B2 | Friction reduction of acidic treatment fluids | GFER, FGB, NSF | DNM1 261/4885APP 3830/4885TP53 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.